Galega G 2mg/500mg Tablet is a combination oral antidiabetic medication containing Glimepiride (2mg) and Metformin (500mg), designed to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby lowering blood glucose levels. Metformin, a biguanide, works primarily by reducing hepatic glucose production and improving insulin sensitivity in peripheral tissues, which helps in enhancing glucose uptake and utilization. The synergistic action of these two agents provides effective blood sugar regulation, making Galega G suitable for patients inadequately controlled by diet, exercise, and monotherapy. This combination helps reduce fasting and postprandial blood glucose levels, contributing to better overall diabetes management and reducing the risk of complications associated with hyperglycemia. Galega G should be taken as prescribed by a healthcare professional, typically once or twice daily with meals to minimize gastrointestinal side effects commonly associated with Metformin. Regular monitoring of blood glucose, renal function, and liver function is recommended during therapy. Patients should be advised on lifestyle modifications, including diet and exercise, to optimize treatment outcomes. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoglycemia.